Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 153
Filter
1.
Phys Rev Lett ; 120(14): 143002, 2018 Apr 06.
Article in English | MEDLINE | ID: mdl-29694134

ABSTRACT

We have made precise measurements of the cyclotron frequency ratios H_{3}^{+}/HD^{+} and H_{3}^{+}/^{3}He^{+} and observe that different H_{3}^{+} ions result in different cyclotron frequency ratios. We interpret these differences as due to the molecular rotational energy of H_{3}^{+} changing its inertial mass. We also confirm that certain high J, K rotational levels of H_{3}^{+} have mean lifetimes exceeding several weeks. From measurements with the lightest H_{3}^{+} ion we obtain lower limits on the atomic masses of deuterium and helium-3 with respect to the proton.

2.
Eur J Pain ; 19(7): 889-98, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25388329

ABSTRACT

BACKGROUND: Neuropathic pain is a common complication of treatment with the anti-neoplastic drug paclitaxel. Animal studies suggest neuroinflammation and transient receptor potential channels TRPA1 and TRPV4 are involved in the pathogenesis of pain in this condition. However, how neuroinflammation and TRPA1 and TRPV4 are linked to cause pain in paclitaxel-treated animals is not known. METHODS: Paclitaxel-induced pain was modelled by IP injection of paclitaxel (16 mg/kg) once a week for 5 weeks. The role of toll-like receptor 4 (TLR-4) in tumour necrosis factor-α (TNF-α) production and the effect of TNF-α on the expression of TRPA1 and TRPV4 were evaluated in vitro and in vivo. TNF-α signalling in dorsal root ganglion (DRG) was blocked by expressing soluble TNF receptor I (TNFsR) from a herpes simplex virus (HSV)-based vector (vTNFsR). RESULTS: Paclitaxel treatment increased the expression and release of TNF-α in satellite glial cells and increased the expression of TRPA1 and TRPV4 in DRG neurons in animals. In vitro, paclitaxel enhanced the expression and release of TNF-α in enriched primary satellite glial cells, an effect that was blocked by an inhibitor of TLR-4. Direct application of TNF-α to primary DRG neurons in culture up-regulated the expression of TRPA1 and TRPV4. In vivo, vector-mediated TNFsR release from DRG neurons reduced paclitaxel-induced up-regulation of TRPA1 and TRPV4 expression and prevented paclitaxel-induced pain. CONCLUSION: These results suggest that paclitaxel activation of TLR-4 to cause release of TNF-α from satellite glial cells increases the expression of TRPA1 and TRPV4 in DRG neurons to cause neuropathic pain.


Subject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Neuralgia/chemically induced , Paclitaxel/adverse effects , Toll-Like Receptor 4/metabolism , Tumor Necrosis Factor-alpha/biosynthesis , Animals , Behavior, Animal/drug effects , Ganglia, Spinal/drug effects , Male , Neuralgia/psychology , Neuroglia/drug effects , Primary Cell Culture , Rats , Rats, Sprague-Dawley , Satellite Cells, Perineuronal/metabolism , TRPA1 Cation Channel , TRPC Cation Channels/biosynthesis , TRPC Cation Channels/genetics , TRPV Cation Channels/biosynthesis , TRPV Cation Channels/genetics , Toll-Like Receptor 4/antagonists & inhibitors , Toll-Like Receptor 4/genetics , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation/drug effects
3.
Gene Ther ; 19(1): 101-8, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21614028

ABSTRACT

Opiate/narcotic analgesics are the most effective treatments for chronic severe pain, but their clinical utility is often hampered by the development of analgesic tolerance. Recent evidence suggests chronic morphine may activate glial cells to release proinflammatory cytokines. In this study, we used herpes simplex virus (HSV) vector-based gene transfer to dorsal root ganglion to produce a local release of p55 tumor necrosis factor (TNF) soluble receptor in the spinal cord in rats with morphine tolerance. Subcutaneous inoculation of HSV vectors expressing p55 TNF soluble receptor into the plantar surface of the hindpaws enhanced the antinociceptive effect of acute morphine in rats. Subcutaneous inoculation of those vectors into hindpaws also delayed the development of chronic morphine tolerance in rats. TNF soluble receptor expressed by HSV vector reduced gene transcription of spinal TNFα and interleukin-1ß (IL-1ß) induced by repeated morphine. Furthermore, we found that TNF soluble receptor mediated by HSV reversed the upregulation of protein level of TNFα and IL-1ß and phosphorylation of p38 mitogen-activated protein kinase induced by repeated morphine. These results support the concept that proinflammatory cytokines may have an important role in the pathogenesis induced by morphine. This study provides a novel approach to treating morphine tolerance.


Subject(s)
Drug Tolerance , Morphine/pharmacology , Receptors, Tumor Necrosis Factor/immunology , Transgenes , Analgesics/administration & dosage , Analgesics/pharmacology , Animals , Behavior, Animal , Ganglia, Spinal/immunology , Ganglia, Spinal/metabolism , Gene Expression Regulation , Gene Transfer Techniques , Genetic Therapy , Genetic Vectors/genetics , Genetic Vectors/immunology , Genetic Vectors/metabolism , Injections, Subcutaneous , Interleukin-1beta/immunology , Male , Morphine/administration & dosage , Phosphorylation , Rats , Rats, Sprague-Dawley , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor/metabolism , Simplexvirus/genetics , Simplexvirus/immunology , Simplexvirus/metabolism , Spinal Cord/immunology , Spinal Cord/metabolism , Time Factors , Transcription, Genetic , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/metabolism
4.
Gene Ther ; 19(11): 1107-13, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22089494

ABSTRACT

We previously reported regulated expression of erythropoietin (EPO) over 4 weeks in the peripheral nerve in vivo, using a herpes simplex virus (HSV)-based vector containing a Tet-on regulatable gene expression cassette. To create a vector that would be appropriate for the treatment of chronic neuropathy, we constructed a HSV vector with expression of EPO under the control of the Tet-on system in which the HSV latency-associated promoter 2 element was used to drive the expression of the Tet-on transactivator. EPO expression from the vector was tightly controlled by administration of doxycycline (DOX) in vitro. One month after inoculation of the vector to transduce dorsal root ganglion (DRG) in vivo, administration of DOX-containing chow-induced expression of EPO. Mice with streptozotocin-induced diabetes, inoculated with the vector, were protected against the development of neuropathy by continuous administration of DOX-containing chow over the course of 3 months. Identical results were achieved when DOX was administered every other week over 3 months of diabetes, but administration of DOX, 1 week out of 3, provided only partial protection against the development of neuropathy. Taken together, these results suggest such a vector is well suited for clinical trial for the treatment of chronic or subacutely developing neuropathy.


Subject(s)
DNA-Binding Proteins/genetics , Erythropoietin/genetics , Gene Expression Regulation , Genetic Vectors/genetics , Membrane Proteins/genetics , Promoter Regions, Genetic , Simplexvirus/genetics , Animals , Cell Line , Diabetic Neuropathies/genetics , Diabetic Neuropathies/therapy , Disease Progression , Doxycycline/pharmacology , Erythropoietin/metabolism , Gene Expression Regulation/drug effects , Gene Order , Genetic Therapy , Humans , Male , Mice
5.
Gene Ther ; 19(9): 907-14, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22052241

ABSTRACT

We evaluated the therapeutic effect of erythropoietin (EPO) delivered by direct injection of a nonreplicating herpes simplex virus (HSV)-based vector coding for EPO (vEPO) in a model of cervical hemicord contusion at C7. At 1 h after spinal cord injury (SCI), either vEPO or control vector carrying a reporter gene (vC) was injected into the cord above and below the lesion. Animals injected with vEPO showed a statistically significant improvement in the ipsilateral forelimb function, as measured by open-field evaluation of motor performance, forelimb reaching in the cylinder test and misplacement in grid walk. This correlated with preservation of gray matter in the area of the lesion. There was also mild but significant improvement of hindlimb motor function measured by Basso-Beattie-Bresnahan score and computerized gait analysis in vEPO compared with control vector-injected animals. Microtubule-associated protein tau, phosphorylated and nonphosphorylated neurofilament protein and the synaptic proteins synaptophysin and PSD-95 were all significantly increased in the spinal cord of vEPO-treated animals compared with control vector-injected animals. These data suggest that gene transfer of EPO after cervical SCI by minimizing the injury size and enhancing tissue sparing preserves large-caliber axons and promotes synaptogenesis.


Subject(s)
Contusions/therapy , Erythropoietin/genetics , Genetic Vectors , Simplexvirus/genetics , Spinal Cord Injuries/therapy , Transfection , Animals , Female , Forelimb/physiopathology , Hindlimb/physiopathology , Microtubule-Associated Proteins/metabolism , Neurofilament Proteins/metabolism , Rats , Rats, Sprague-Dawley , Recovery of Function , Spinal Cord/cytology , Spinal Cord/metabolism , Spinal Cord Injuries/physiopathology
7.
Gene Ther ; 16(4): 455-60, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19242524

ABSTRACT

Gene transfer to the dorsal root ganglion using replication defective herpes simplex virus (HSV)-based vectors reduces pain-related behaviors in rodent models having inflammatory pain, neuropathic pain and pain caused by cancer in bone. HSV vectors engineered to produce inhibitory neurotransmitters, including the delta opioid agonist peptide enkephalin, the mu opioid agonist peptide endomorphin-2 and glutamic acid decarboxylase (GAD), to effect the release of gamma amino butyric acid (GABA) act to inhibit nociceptive neurotransmission at the first synapse between primary nociceptive and second-order neuron in the dorsal horn of the spinal cord. HSV vectors engineered to release anti-inflammatory peptides, including interleukin (IL)-4, IL-10 and the p55 soluble tumor necrosis factor alpha (TNFalpha) receptor reduce neuroimmune activation in the spinal dorsal horn. The path leading from preclinical animal studies to the ongoing phase 1 human trial of the enkephalin-producing vector in patients with pain from cancer, and plans for an efficacy trial with an opioid-producing vector in inflammatory pain and an efficacy trial with a GAD-producing vector in diabetic neuropathic pain are outlined.


Subject(s)
Genetic Therapy/methods , Genetic Vectors , Pain Management , Simplexvirus/genetics , Animals , Chronic Disease , Clinical Trials, Phase I as Topic , Enkephalins/biosynthesis , Gene Transfer Techniques , Glutamate Decarboxylase/biosynthesis , Humans , Mice , gamma-Aminobutyric Acid/biosynthesis
9.
Gene Ther ; 15(3): 183-90, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18033311

ABSTRACT

To dissect the molecular basis of the neuroimmune response associated with the genesis of inflammatory (nociceptive) pain, we constructed a herpes simplex virus-based gene transfer vector to express the antiinflammatory cytokine interleukin-10 (IL-10), and used it to examine the effect of IL-10 expression in activated microglial cells in vitro, and in inflammatory pain in vivo. IL-10 reduced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) and decreased the expression of full-length membrane spanning tumor necrosis factor-alpha (mTNFalpha) following lipopolysaccharide stimulation of microglia in vitro. IL-10 also reduced intracellular cleavage of mTNFalpha and release of the soluble cleavage product sTNFalpha. Similar effects on TNFalpha expression were observed when the cells were pretreated with a p38 MAPK inhibitor. In animals, injection of a dilute solution of formalin in the skin resulted in an increase in mTNFalpha in spinal dorsal horn, without detectable sTNFalpha. Local release of IL-10 achieved by gene transfer reduced the number of spontaneous flinches in the early and delayed phases of the formalin test of inflammatory pain. The effect of IL-10 on nocisponsive behavior correlated with a block in phosphorylation of p38 and reduced expression of 26 kDa mTNFalpha in spinal microglia. The results emphasize the key role played by membrane TNFalpha in the spinal neuroimmune response in pain caused by peripheral inflammation.


Subject(s)
Genetic Therapy/methods , Interleukin-10/genetics , Microglia/immunology , Pain Management , Simplexvirus/genetics , Tumor Necrosis Factor-alpha/metabolism , Animals , Cells, Cultured , Down-Regulation , Formaldehyde , Lipopolysaccharides/pharmacology , Male , Models, Animal , Myelitis/pathology , Myelitis/therapy , Phosphorylation , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Spinal Cord/immunology , Transduction, Genetic/methods , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/genetics , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism
10.
Diabetologia ; 50(7): 1550-8, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17508196

ABSTRACT

AIMS/HYPOTHESIS: The aim of this study was to determine whether prolonged expression of neurotrophin-3 (NT-3) in mice, achieved by herpes simplex virus (HSV)-mediated gene transfer with gene expression under the control of an HSV latency promoter, can provide protection against the progression of diabetic neuropathy over a 6 month period. MATERIALS AND METHODS: Mice with diabetes induced by streptozotocin were inoculated s.c. into both hind feet with a non-replicating HSV vector containing the coding sequence for NT-3 under the control of the HSV latency-associated promoter 2 (LAP2) elements or with a control vector. Nerve function was evaluated by electrophysiological and behavioural measures over the course of 6 months after the onset of diabetes. RESULTS: Animals inoculated with the NT-3-expressing vector, but not animals inoculated with control vector, showed preservation of sensory and motor nerve amplitude and conduction velocity measured electrophysiologically, small fibre sensory function assessed by withdrawal from heat, autonomic function measured by pilocarpine-induced sweating, skin innervation assessed by protein gene product 9.5 staining of axons, and density of calcitonin gene-related peptide terminals in the spinal cord measured by immunohistochemistry 5.5 months after vector inoculation. CONCLUSIONS/INTERPRETATION: These results indicate that the continuous production of NT-3 by LAP2-driven expression of the transgene from an HSV vector over a 6 month period protects against progression of diabetic neuropathy in mice, and provide a proof-of-principle demonstration for the development of a novel therapy for preventing the progression of diabetic neuropathy.


Subject(s)
Diabetic Neuropathies/therapy , Neurons/metabolism , Animals , Axons/metabolism , Calcitonin/metabolism , Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Experimental/therapy , Genetic Therapy/methods , Male , Mice , Pilocarpine/pharmacology , Polyneuropathies/pathology , Rats , Rats, Sprague-Dawley , Simplexvirus/genetics , Spinal Cord/metabolism
11.
Gene Ther ; 14(13): 1010-6, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17443214

ABSTRACT

We examined the role of spinal tumor necrosis factor-alpha (TNFalpha) in neuropathic pain of peripheral nerve origin. Two weeks after selective L5 spinal nerve ligation (SNL), rats exhibiting mechanical allodynia and thermal hyperalgesia showed a marked increase in full-length membrane-associated TNFalpha (mTNFalpha) in the dorsal horn of spinal cord, in the absence of detectable soluble TNFalpha peptide. Local release of the soluble p55 TNF receptor, achieved by herpes simplex virus vector-based gene transfer to dorsal root ganglion, resulted in a reduction of mTNFalpha and concomitant reductions in interleukin-1beta and phosphorylated p38 MAP kinase. Subcutaneous inoculation of soluble p55 TNF receptor expressing HSV vector into the plantar surface of the hind foot ipsilateral to the ligation 1 week before SNL delayed the development of both mechanical allodynia and thermal hyperalgesia; subcutaneous inoculation into the hind foot ipsilateral to the ligation 1 week after SNL resulted in a statistically significant reduction in mechanical allodynia and thermal hyperalgesia that was apparent 1 week after inoculation. These results suggest a novel 'reverse signaling' through glial mTNFalpha, which may be exploited to downregulate the neuroimmune reaction in spinal cord to reduce chronic neuropathic pain.


Subject(s)
Genetic Therapy/methods , Pain Management , Receptors, Tumor Necrosis Factor/genetics , Signal Transduction/physiology , Transduction, Genetic/methods , Tumor Necrosis Factor-alpha/metabolism , Animals , Astrocytes/immunology , Blotting, Western/methods , Chronic Disease , Enzyme-Linked Immunosorbent Assay , Gene Expression , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Green Fluorescent Proteins/genetics , Immunohistochemistry , Microscopy, Fluorescence , Models, Animal , Pain/etiology , Pain/immunology , Rats , Rats, Sprague-Dawley , Receptors, Tumor Necrosis Factor/metabolism , Simplexvirus/genetics , Spinal Cord Injuries/complications , Spinal Cord Injuries/immunology , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/immunology
12.
J Clin Endocrinol Metab ; 91(11): 4344-51, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16912122

ABSTRACT

CONTEXT: Due to the Chornobyl accident, millions were exposed to radioactive isotopes of iodine and some received appreciable iodine 131 (131I) doses. A subsequent increase in thyroid cancer has been largely attributed to this exposure, but evidence concerning autoimmune thyroiditis (AIT) remains inconclusive. OBJECTIVE: The objective of the study was to quantify risk of AIT after 131I exposure. DESIGN/SETTING/PARTICIPANTS: Baseline data were collected from the first screening cycle (1998-2000) of a large cohort of radiation-exposed individuals (n = 12,240), residents of contaminated, iodine-deficient territories of Ukraine. Study individuals were under the age of 18 yr on April 26, 1986, and had thyroid radioactivity measurements made shortly after the accident. OUTCOMES: AIT was defined a priori based on various combinations of elevated antibodies to thyroid peroxidase (ATPO), TSH, and clinical findings; elevated ATPO were considered to be an indicator of thyroid autoimmunity. RESULTS: No significant association was found between 131I thyroid dose estimates and AIT, but prevalence of elevated ATPO demonstrated a modest, significant association with 131I that was well described by several concave models. This relationship was apparent in individuals with moderately elevated ATPO and euthyroid, thyroid disease-free individuals. CONCLUSIONS: Twelve to 14 yr after the Chornobyl accident, no radiation-related increase in prevalence of AIT was found in a large cohort study, the first in which 131I thyroid doses were estimated using individual radioactivity measurements. However, a dose-response relationship with ATPO prevalence raises the possibility that clinically important changes may occur over time. Thus, further follow-up and analysis of prospective data in this cohort are necessary.


Subject(s)
Carcinoma/epidemiology , Chernobyl Nuclear Accident , Iodine Radioisotopes/adverse effects , Neoplasms, Radiation-Induced/epidemiology , Thyroid Diseases/epidemiology , Thyroid Neoplasms/epidemiology , Thyroiditis, Autoimmune/epidemiology , Adolescent , Autoantibodies/blood , Autoantigens/immunology , Child , Child, Preschool , Cohort Studies , Cross-Sectional Studies , Female , Humans , Infant , Infant, Newborn , Iodide Peroxidase/immunology , Iron-Binding Proteins/immunology , Male , Mass Screening/methods , Radiation Dosage , Ukraine/epidemiology
13.
Gene Ther ; 12(18): 1377-84, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15843809

ABSTRACT

We examined the utility of herpes simplex virus (HSV) vector-mediated gene transfer of vascular endothelial growth factor (VEGF) in a mouse model of diabetic neuropathy. A replication-incompetent HSV vector with VEGF under the control of the HSV ICP0 promoter (vector T0VEGF) was constructed. T0VEGF expressed and released VEGF from primary dorsal root ganglion (DRG) neurons in vitro, and following subcutaneous inoculation in the foot, expressed VEGF in DRG and nerve in vivo. At 2 weeks after induction of diabetes, subcutaneous inoculation of T0VEGF prevented the reduction in sensory nerve amplitude characteristic of diabetic neuropathy measured 4 weeks later, preserved autonomic function measured by pilocarpine-induced sweating, and prevented the loss of nerve fibers in the skin and reduction of neuropeptide calcitonin gene-related peptide and substance P in DRG neurons of the diabetic mice. HSV-mediated transfer of VEGF to DRG may prove useful in treatment of diabetic neuropathy.


Subject(s)
Diabetic Neuropathies/prevention & control , Ganglia, Spinal/metabolism , Genetic Therapy/methods , Simplexvirus/genetics , Vascular Endothelial Growth Factor A/genetics , Animals , Diabetes Mellitus, Experimental , Diabetic Neuropathies/metabolism , Diabetic Neuropathies/physiopathology , Electrophysiology , Ganglia, Spinal/pathology , Ganglia, Spinal/virology , Gene Expression , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Image Processing, Computer-Assisted , Immunohistochemistry/methods , Male , Mice , Pain Measurement , Rats , Rats, Sprague-Dawley , Skin/innervation , Skin/metabolism , Transduction, Genetic/methods , Vascular Endothelial Growth Factor A/analysis , Vascular Endothelial Growth Factor A/metabolism
15.
J Neurovirol ; 7(5): 476-80, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11582520

ABSTRACT

The entry of herpes simplex virus (HSV)-1 into cells is a complex process mediated in part by the binding of the HSV glycoprotein D (gD) to a specific cellular receptor identified as HveC, or nectin-1. We examined the distribution of HveC in sensory and motor neurons of the peripheral nervous system (PNS) by immunocytochemistry. HveC is expressed at high levels in sensory neurons of dorsal root ganglion and their peripheral axons, at lower levels in motor neurons of spinal cord, and without detectable expression in motor nerve terminals at the neuromuscular junction. These results have implications regarding the tropism of HSV to specific neuronal populations, and for the construction of HSV-based vectors for the peripheral nervous system.


Subject(s)
Cell Adhesion Molecules/biosynthesis , Ganglia, Spinal/metabolism , Motor Neurons/metabolism , Nerve Tissue Proteins/biosynthesis , Neurons, Afferent/metabolism , Peripheral Nerves/metabolism , Simplexvirus/physiology , Animals , Antibodies, Monoclonal/immunology , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/immunology , Diaphragm/innervation , Gene Expression Regulation, Viral , Humans , Immunoenzyme Techniques , Male , Mice , Nectins , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/immunology , Rats , Rats, Sprague-Dawley , Species Specificity , Toes/innervation
16.
Stem Cells ; 19(5): 358-77, 2001.
Article in English | MEDLINE | ID: mdl-11553845

ABSTRACT

Herpes simplex virus (HSV) is a neurotropic DNA virus. The viral genome is large (152 kb), and many genes are dispensable for viral function, allowing insertion of multiple or large transgene expression cassettes. The virus life cycle includes a latent phase, during which the viral genome remains as a stable episomal element within neuronal nuclei for the lifetime of the host, without disturbing normal function. We have exploited these features of HSV to construct a series of nonpathogenic gene therapy vectors that efficiently deliver therapeutic and experimental transgenes to neural and non-neural tissue. Importantly, transgene expression may be sustained long term; reporter gene expression has been demonstrated for over a year in the nervous system. This article discusses the generation of replication-defective HSV vectors and reviews recent studies investigating their use in several animal models of human disease. We have demonstrated correction or prevention of a number of important neurological phenotypes, including neurodegeneration, chronic pain, peripheral neuropathy, and malignancy. In addition, HSV-mediated transduction of non-neurological tissues allows their use as depot sites for synthesis of circulating and locally acting secreted proteins. New applications for this vector system include the genetic modification of stem cell populations; this may become an important means to direct cellular differentiation or deliver therapeutic genes systemically. Replication-defective HSV vectors are an effective and flexible vehicle for the delivery of transgenes to numerous tissues, with multiple applications.


Subject(s)
Genetic Vectors , Herpesvirus 1, Human/genetics , Herpesvirus 1, Human/physiology , Transgenes , Genes, Reporter , Genome, Viral , Humans , Models, Biological , Mutation , Neoplasms/therapy , Nervous System Diseases/therapy , Phenotype , Time Factors
17.
Clin Chim Acta ; 308(1-2): 79-89, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11412819

ABSTRACT

BACKGROUND: In view of the importance of the diagnosis of rheumatoid arthritis, a novel diagnostic method based on spectroscopic pattern recognition in combination with laboratory parameters such as the rheumatoid factor is described in the paper. Results of a diagnostic study of rheumatoid arthritis employing this method are presented. METHOD: The method uses classification of infrared (IR) spectra of serum samples by means of discriminant analysis. The spectroscopic pattern yielding the highest discriminatory power is found through a complex optimization procedure. In the study, IR spectra of 384 serum samples have been analyzed in this fashion with the objective of differentiating between rheumatoid arthritis and healthy subjects. In addition, the method integrates results from the classification with levels of the rheumatoid factor in the sample by optimized classifier weighting, in order to enhance classification accuracy, i.e. sensitivity and specificity. RESULTS: In independent validation, sensitivity and specificity of 84% and 88%, respectively, have been obtained purely on the basis of spectra classification employing a classifier designed specifically to provide robustness. Sensitivity and specificity are improved by 1% and 6%, respectively, upon inclusion of rheumatoid factor levels. Results for less robust methods are also presented and compared to the above numbers. CONCLUSION: The discrimination between RA and healthy by means of the pattern recognition approach presented here is feasible for IR spectra of serum samples. The method is sufficiently robust to be used in a clinical setting. A particular advantage of the method is its potential use in RA diagnosis at early stages of the disease.


Subject(s)
Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/diagnosis , Rheumatoid Factor/blood , Adolescent , Data Display , Discriminant Analysis , Feasibility Studies , Female , Humans , Male , Middle Aged , Pattern Recognition, Automated , ROC Curve , Reference Values , Sensitivity and Specificity , Spectrophotometry, Infrared/instrumentation
18.
Exp Neurol ; 169(2): 231-8, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11358438

ABSTRACT

Previous studies have demonstrated that either the neurotrophin glial-derived neurotrophic factor (GDNF) or the antiapoptotic peptide Bcl-2 delivered into striatum by a viral vector protects dopaminergic neurons of the substantia nigra in vivo from degeneration induced by the administration of the neurotoxin 6-hydroxydopamine (6-OHDA). In this study we used recombinant, replication-incompetent, genomic herpes simplex virus-based vectors to deliver the genes coding for Bcl-2 and GDNF into rat substantia nigra (SN) 1 week prior to 6-OHDA injection into the striatum. Vector-mediated expression of either Bcl-2 or GDNF alone each resulted in a doubling in cell survival as measured by retrograde labeling with fluorogold (FG) and a 50% increase in tyrosine hydroxylase-immunoreactive (TH-IR) neurons in the lesioned SN compared to the unlesioned side. Gene transfer of Bcl-2 and GDNF were equivalent in this effect. Coadministration of the Bcl-2-expressing vector with the GDNF-expressing vector improved the survival of lesioned SN neurons as measured by FG labeling by 33% and by the expression of TH-IR by 15%. These results suggest that the two factors delivered together act in an additive fashion to improve DA cell survival in the face of 6-OHDA toxicity.


Subject(s)
Corpus Striatum/physiology , Dopamine/physiology , Gene Transfer Techniques , Genes, bcl-2 , Nerve Growth Factors , Nerve Tissue Proteins/physiology , Neurons/physiology , Oxidopamine/toxicity , Proto-Oncogene Proteins c-bcl-2/metabolism , Substantia Nigra/physiology , Tyrosine 3-Monooxygenase/analysis , Animals , Corpus Striatum/drug effects , Corpus Striatum/pathology , Dextroamphetamine/pharmacology , Female , Functional Laterality , Genes, Reporter , Genetic Therapy/methods , Genetic Vectors , Glial Cell Line-Derived Neurotrophic Factor , Humans , Motor Activity/drug effects , Nerve Degeneration/genetics , Nerve Degeneration/prevention & control , Nerve Tissue Proteins/genetics , Neurons/cytology , Neurons/drug effects , Proto-Oncogene Proteins c-bcl-2/genetics , Rats , Rats, Sprague-Dawley , Rotation , Simplexvirus , beta-Galactosidase/analysis , beta-Galactosidase/genetics
19.
Gene Ther ; 8(7): 551-6, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11319622

ABSTRACT

Endogenous opiate peptides acting pre- and post-synaptically in the dorsal horn of spinal cord inhibit transmission of nociceptive stimuli. We transfected neurons of the dorsal root ganglion in vivo by footpad inoculation with 30 microl (3 x 10(7) p.f.u.) of a replication-incompetent (ICP4-deleted) herpes simplex virus (HSV) vector with a cassette containing a portion of the human proenkephalin gene coding for 5 met- and 1 leu-enkephalin molecules under the control of the human cytomegalovirus immediate-early promoter (HCMV IEp) inserted in the HSV thymidine kinase (tk) locus. Vector-directed expression of enkephalin produced a significant antinociceptive effect measured by the formalin footpad test, that was most prominent in the delayed ("tonic") phase 20-70 min after the administration of formalin. The magnitude of the antinociceptive effect diminished over 4 weeks after transduction, but reinoculation of the vector reestablished the analgesic effect, without evidence for the development of tolerance. The antinociceptive effect was blocked completely by intrathecal naltrexone. These results suggest that gene therapy with an enkephalin-producing herpes-based vector may prove useful in the treatment of pain.


Subject(s)
Analgesia/methods , Enkephalins/genetics , Ganglia, Spinal/metabolism , Genetic Therapy/methods , Genetic Vectors/therapeutic use , Protein Precursors/genetics , Simplexvirus/genetics , Animals , Enkephalins/metabolism , Formaldehyde , Humans , Male , Naltrexone/pharmacology , Pain Measurement , Protein Precursors/metabolism , Rats , Rats, Wistar , Transfection
20.
Exp Neurol ; 168(2): 225-30, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11259110

ABSTRACT

Proximal axotomy in adult animals results in delayed death of motor neurons. Features characteristic of both necrosis and apoptosis have been described in motor neurons of the spinal cord following proximal avulsion of the ventral roots. We have previously demonstrated that a genomic herpes simplex virus (HSV)-based vector expressing the anti-apoptotic peptide Bcl-2 protects dopaminergic neurons of the substantia nigra from neurotoxin-induced apoptotic cell death and preserves the neurotransmitter phenotype of those cells. In this study we examined whether the same vector could protect adult rat lumbar motor neurons from cell death following proximal ventral root avulsion. Injection of the Bcl-2-expressing vector 1 week prior to root avulsion increased the survival of lesioned motor neurons, determined by retrograde Fluorogold labeling, by 50%. The Bcl-2-expressing vector did not preserve choline acetyltransferase neurotransmitter phenotype of the lesioned cells. These results shed light on the mechanism of cell death following axonal injury, and have implications for developing an effective treatment for the clinical problem of proximal root avulsion.


Subject(s)
Anterior Horn Cells/metabolism , Genetic Vectors/therapeutic use , Motor Neurons/metabolism , Nerve Degeneration/prevention & control , Proto-Oncogene Proteins c-bcl-2/metabolism , Radiculopathy/metabolism , Animals , Anterior Horn Cells/drug effects , Cell Death/drug effects , Cell Death/physiology , Choline O-Acetyltransferase/metabolism , Genetic Vectors/metabolism , Humans , Male , Motor Neurons/drug effects , Motor Neurons/pathology , Radiculopathy/complications , Radiculopathy/pathology , Rats , Rats, Sprague-Dawley , Simplexvirus
SELECTION OF CITATIONS
SEARCH DETAIL
...